New pill aims to silence hepatitis b virus in patients with stubborn Low-Level infection
NCT ID NCT06644417
First seen Sep 30, 2025 · Last updated Jun 21, 2026 · Updated 34 times
Summary
This study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605 could push the virus below detectable levels and improve safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION WITH LLV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, 100015, China
-
Beijing Youan Hospital, Capital Medical Universitybeijing Institute of Hepatology
Beijing, Beijing Municipality, 100054, China
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210000, China
-
Lishui People's Hospital
Lishui, Zhejiang, 323000, China
-
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, 350001, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200000, China
-
Shandong Public Health Clinical Center
Jinan, Shandong, 250102, China
-
Shanghai Tongren Hospital
Shanghai, Shanghai Municipality, 200336, China
-
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, 215131, China
-
The First Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, 310006, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710000, China
-
The Second XIANGYA Hospital Of Central South University
Changsha, Hunan, 410008, China
-
The sixth people's Hospital Of Shenyang
Shenyang, Liaoning, 110001, China
-
Yueyang Central Hospital
Yueyang, Hunan, 414000, China
-
Zhengzhou No.6 peoples Hospital
Zhengzhou, Henan, 450000, China
-
Zunyi Medical University Affiliated Hospital
Zunyi, Guizhou, 563000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQA3605 tablets (a core protein regulator)
What this could lead to
If successful, this could offer a new treatment option to help people with chronic hepatitis B achieve undetectable virus levels, potentially reducing liver damage and disease progression.
What could go wrong
This is an early-phase (Phase II) trial with only 122 participants, so results may not apply to everyone. The drug may not work better than current therapy, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.